Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14528479 | 0.85 | RAPGEF4 (0.45) | RAPGEF4CYP1A2 | |
| SCHEMBL5515978 | 0.85 | RAPGEF4 (0.36) | RAPGEF4 | |
| SCHEMBL16838143 | 0.83 | RAPGEF4 (0.35) | RAPGEF4TSHRKCNH2CYP1A2 | |
| SCHEMBL5513274 | 0.83 | RAPGEF4 (0.35) | RAPGEF4DHFRCYP1A2 | |
| SCHEMBL5517867 | 0.83 | RAPGEF4 (0.35) | RAPGEF4CES2CES1 | |
| SCHEMBL5518604 | 0.80 | RAPGEF4 (0.35) | RAPGEF4TSHRKCNH2 | |
| SCHEMBL5516191 | 0.80 | HDAC1 (0.41) | RAPGEF4TSHRKCNH2 | |
| SCHEMBL16838142 | 0.79 | RAPGEF4 (0.33) | RAPGEF4 | |
| SCHEMBL16838140 | 0.79 | RAPGEF4 (0.33) | RAPGEF4 | |
| SCHEMBL25082732 | 0.78 | KCNH2 (0.34) | RAPGEF4TSHRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| WO-2021250461-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-12-16 | — | — | WO | disclosed |
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10364228-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| CN-106536525-B | Compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-05-03 | — | — | CN | disclosed |
| US-10196376-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-01-17 | — | — | US | disclosed |
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20110183977-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-7906529-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7879795-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7358370-B2 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | SERENEX, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2007054623-A2 | MAMMALIAN HEDGEHOG SIGNALING INHIABITORS | LICENTIA OY (FI) | 2007-05-18 | — | — | WO | disclosed |
| US-20050239841-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005051381-A1 | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | RAPGEF4 3379/4885CES2 332/4885CES1 46/4885 |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | RAPGEF4 2773/4885CES2 3423/4885CES1 1054/4885 |
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | HAVCR2, HDGF, AZI2 | RAPGEF4 3379/4885CES2 332/4885CES1 46/4885 |
| US-10196376-B2 | Hepatitis B antiviral agents | HAVCR2, EIF2AK2, IRF3 | RAPGEF4 2681/4885CES2 1573/4885CES1 323/4885 |
| US-10364228-B2 | Azepane derivatives and methods of treating hepatitis B infections | HAVCR2, HDGF, AZI2 | RAPGEF4 3379/4885CES2 332/4885CES1 46/4885 |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | RAPGEF4 1807/4885CES2 111/4885CES1 203/4885 |
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, SLC10A1 | RAPGEF4 3963/4885CES2 742/4885CES1 83/4885 |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | RAPGEF4 3379/4885CES2 332/4885CES1 46/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | RAPGEF4 4313/4885CES2 4573/4885CES1 2298/4885 |
| US-20050239841-A1 | New compounds | MCHR1, NPY1R, HCRTR1 | RAPGEF4 2333/4885CES2 2387/4885CES1 1864/4885 |
| US-20110183977-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | RAPGEF4 3156/4885CES2 4297/4885CES1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.